Stock ARDEA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Ardea Biosciences, Inc.

Equities

US03969P1075

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Ardea Biosciences, Inc.
2012 SANOFI : AstraZeneca hungry to refill medicine cabinet RE
2012 SANOFI : GSK goes hostile with $2.6 billion Human Genome offer RE

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
SANOFI : AstraZeneca hungry to refill medicine cabinet
RE
SANOFI : GSK goes hostile with $2.6 billion Human Genome offer
RE
Ardea Biosciences, Inc. : Biotech targets fight back as Big Pharma circles
RE
Ardea Biosciences, Inc. : Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Ardea Biosciences, Inc.
PR
Ardea Biosciences, Inc. : Warner Chilcott to explore sale of company
RE
Ardea Biosciences, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Ardea Biosciences, Inc.
BU
SANOFI : AstraZeneca CEO quits as drug sales tumble
RE
Ardea Biosciences, Inc. : Watson to buy Actavis for at least $5.6 billion
RE
Ardea Biosciences, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Ardea Biosciences, Inc.
PR
Ardea Biosciences, Inc. : Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Law Offices of Howard G. Smith
BU
Ardea Biosciences, Inc. : Ryan & Maniskas, LLP Announces Investigation of Ardea Biosciences, Inc.
BU
Ardea Biosciences, Inc. : Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardea Biosciences, Inc.
BU
Ardea Biosciences, Inc. : Law Firm Brower Piven Announces Investigation in Connection With the Acquisition of Ardea Biosciences, Inc. by AstraZeneca Biopharmaceuticals Inc.
BU
Ardea Biosciences, Inc. : Ardea Biosciences Merger Investigated by the Securities Attorneys at The Briscoe Law Firm and Powers Taylor, LLP
BU
Ardea Biosciences, Inc. : AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
PU
Ardea Biosciences, Inc. : Ardea Biosciences to Present at Upcoming Investor Conferences
PU
Ardea Biosciences, Inc. : Ardea Biosciences to Present at Upcoming Investor Conferences
PU
Ardea Biosciences, Inc. : Ardea Biosciences Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
PU
Ardea Biosciences, Inc. : Ardea Biosciences Prices Public Offering of Common Stock
PU
Ardea Biosciences, Inc. : Ardea Biosciences Announces Proposed Public Offering of Common Stock
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Ardea Biosciences, Inc.